

TRacking


Real world European registry of NTRK fusions and other rare actionable fusions

Nom du Centre porteur: CLB

Nom et mail du médecin responsable qui peut être contacter


Pr Jean-Yves BLAY – jean-yves.blay@lyon.unicancer.fr

Centres participants



Molécules, schéma de traitement

No treatment modification : Real life follow-up



Indication : cancer solide présentant une fusion actionnable

Principaux critères d'inclusion

- Patient with histologically-confirmed cancer treated in a European expert center (EURACAN or off grid cancer centers),
- Patient harboring a rare actionable fusion,
- Availability of clinical and demographic data, information on treatment and clinical outcome.
- Adult, ≥ 18 years old,
- Patient should understand, sign and date the written voluntary informed consent form.

Endpoint et stat succinctes

- Endpoint 1aire : To describe the survival rate of patients with solid cancers harboring an actionable fusion in real-life practice, according to overall survival (OS)
- Endpoints 2aire :
To further describe the management of patient with solid cancers harboring an actionable fusion in real-life practice
To document the clinical activity of fusion-targeting treatments
To assess the safety of treatment targeting the actionable fusion
- Nombre de patients nécessaires : 250

Non-exhaustive fusion listing

ALK-PCDH15	RAPGEF3-ALK	MAD1L1-BRAF	FGFR4-STRN	RAB14-NTRK3
ASXL2-ALK	SQSTM1-ALK	PIBF1-BRAF	NSD1-FGFR4	RBPMS-NTRK3
ATIC-ALK	STRN-ALK	RECQL-BRAF	CTNND1-NTRK1	SPECC1L-NTRK3
CLIP1-ALK	THBS1-ALK	RNF11-BRAF	GON4L-NTRK1	TBX19-NTRK3
CLTC-ALK	TIMP3-ALK	SKAP2-BRAF	KHDRBS1-NTRK1	VIM-NTRK3
CRIM1-ALK	TNS1-ALK	SND1-BRAF	KIRREL-NTRK1	COL1A1-PDGFB
DCTN1-ALK	TPM3-ALK	SYPL1-BRAF	LMNA-NTRK1	CCDC6-RET
EHBP1-ALK	TRAF3-ALK	TRIM24-BRAF	MYO5A-NTRK1	KIF5B-RET
EMILIN1-ALK	TRIM63-ALK	TRIM33-BRAF	PRDX1-NTRK1	LMNA-RET
EML4-ALK	VCL-ALK	WDR91-BRAF	TP53-NTRK1	MYH10-RET
FLNA-ALK	AGAP3-BRAF	ERBB2-PTPN13	TPM3-NTRK1	MYH9-RET
FN1-ALK	AGK-BRAF	THBS1-ERBB2	TPR-NTRK1	MYO5A-RET
FXR1-ALK	AKAP9-BRAF	FGFR1-EBF2	VAMP4-NTRK1	CEP85L-ROS1
HMBOX1-ALK	BRAF-DOCK4	FGFR1-FLACC1	SMU1-NTRK2	EEF1G-ROS1
IGFBP5-ALK	CD63-BRAF	FGFR1-FN1	NTRK2-SSH2	GOLGB1-ROS1
KIF5B-ALK	CLIP2-BRAF	FGFR1-HOOK3	STRN3-NTRK2	GOPC-ROS1
LMNA-ALK	CNNM3-BRAF	FGFR1-NSD3	TFG-NTRK2	KIF5B-ROS1
LRRFIP2-ALK	DOCK4-BRAF	FGFR1-STAU2	TLE4-NTRK2	MYO5A-ROS1
MCC-ALK	DST-BRAF	FN1-FGFR1	CNBD1-NTRK3	NUS1-ROS1
MLPH-ALK	DTD1-BRAF	HSPG2-FGFR1	EML4-NTRK3	PLAGL1-ROS1
MTAP-ALK	EEA1-BRAF	FGFR1-HSPG2	ETV6-NTRK3	PWWP2A-ROS1
MYH10-ALK	FNBP1-BRAF	FGFR2-GTF2H2	FANCI-NTRK3	RAD18-ROS1
MYH9-ALK	GNAI1-BRAF	FGFR2-SHTN1	KHDRBS1-NTRK3	RECQL-ROS1
MYO5A-ALK	GSN-BRAF	FGFR3-IGF2	MCTP2-NTRK3	SLC34A2-ROS1
NPAS2-ALK	GTF2I-BRAF	FGFR3-LETM1	MYO5A-NTRK3	TFG-ROS1
NPM1-ALK	KIAA1549-BRAF	FGFR3-TACC3	MYO5A-NTRK3	TPM3-ROS1
OLA1-ALK	KIF5B-BRAF	ARHGEF1-FGFR4	NEO1-NTRK3	TPR-ROS1
PPFIBP1-ALK	LMRD1-BRAF	FGFR4-PDE6B	NTRK3-AKAP13	ZCCHC8-ROS1

→ If a fusion targeting treatment exists, then the patient can be included

Etat d'avancement

Etat du recrutement

- Nombre de patients restant à inclure : 250
- Fermeture prévue le : 31 Déc. 2025
- Nombre de patients inclus : 5

Problème/ Amendement à venir

- **Amendement pour inclure en rétrospectif**
- **Transfert des données aux financeurs à envisager à la fin de l'étude (Roche, Bayer) / accord de chaque centre**